Navigation Links
Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
Date:8/6/2008

Total Drug Market for Pain Will Reach More Than $47 Billion in 2023,

According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although strong opioids and non-steroidal anti-inflammatory drugs (NSAIDs) will continue to dominate the pain market over the next 15 years, novel drug classes will claim over one-fifth of total market share by 2023.

The new special Pharmacor report entitled Novel Approaches to Pain finds that the overall pain market will reach more than $47 billion in 2023 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. From 2008 to 2013, reformulations and emerging therapies in existing drug classes will be the primary drivers of market growth while from 2013 to 2023, growth will result predominantly from the launch of innovative agents representing entirely new drug classes. Therapies representing novel drug classes will expand the pain market by adding to the eight major analgesic drug classes, creating as many as 18 drug classes by 2023, according to the report.

The most successful reformulations and emerging therapies in existing drug classes will be abuse- and dependence-resistant strong opioid formulations, including King Pharmaceuticals/Pain Therapeutics' Remoxy; as well as safer and more tolerable NSAID formulations such as NicOx's naproxcinod and AstraZeneca/POZEN's naproxen/esomeprazole combination; Johnson & Johnson's new dual-acting opioid tapentadol; and longer lasting antimigraine formulations such as GlaxoSmithKline's Treximet.

Of the novel drug classes expected to launch for pain through 2023, the calcitonin gene-related peptide receptor antagonists, growth factor modulators, and subtype-selective ion channel modulators will have the most growth impact owing to their potential efficacy advantages over existing drug classes. All three of these novel drug classes are forecast to attain blockbuster peak-year sales.

"The most commercially promising drugs with novel mechanisms of action are being developed for the treatment of chronic pain that is either inflammatory or neuropathic in origin," said Natalie Taylor, Ph.D., analyst at Decision Resources. "Current therapies for inflammatory pain, such as the NSAID drug class, are plagued by safety concerns when administered over the long-term, while current therapies for neuropathic pain, such as antidepressants and anti-epileptics, are associated with inconsistent efficacy."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite Bad Economy Botox Sales Are Booming
2. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
3. P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth
4. FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008
5. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
6. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
7. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
8. Milestone Scientific Expands Domestic Sales Network With Addition of Three New Dental Distributors
9. Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08
10. Longs Reports Preliminary June Retail Drug Store Sales
11. New Research Covers Current Trends and Future Directions of the High Performing Pharmaceutical District Sales Managers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: